Zevra Therapeutics (ZVRA) Non-Current Debt (2014 - 2025)
Zevra Therapeutics (ZVRA) posted Non-Current Debt of $61.9 million for Q4 2025, up 1.01% on a QoQ basis from $61.3 million in Q3 2025, and up 4.07% year-over-year from $59.5 million in Q4 2024.
Zevra Therapeutics (ZVRA) Non-Current Debt (2014 - 2025) Analysis & Trends
Zevra Therapeutics' Non-Current Debt history runs 8 years deep, the most recent figure standing at $61.9 million for Q4 2025.
- Quarterly Non-Current Debt rose 4.07% year-over-year to $61.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $61.9 million (up 4.07% YoY) and the FY2025 annual result came in at $61.9 million, up 4.07% from the prior year.
- Non-Current Debt was $61.9 million for Q4 2025 at Zevra Therapeutics, up from $61.3 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $61.9 million in Q4 2025 and bottomed at $98000.0 in Q1 2021.
- A 5-year average of $40.6 million and a median of $58.3 million in 2024 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt surged 1074.58% — and 2025, when it grew 4.05%.
- Zevra Therapeutics' Non-Current Debt stood at $98000.0 in 2021, then jumped by 12961.22% to $12.8 million in 2022, then plunged by 60.42% to $5.1 million in 2023, then jumped by 1074.58% to $59.5 million in 2024, then gained by 4.07% to $61.9 million in 2025.
- Business Quant data shows ZVRA's Non-Current Debt at $61.9 million in Q4 2025, $61.3 million in Q3 2025, and $60.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zevra Therapeutics | 239.71 Mn | 39.10 Mn | 34.32 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 61.93 Mn |
| Sep 30, 2025 | 61.31 Mn |
| Jun 30, 2025 | 60.69 Mn |
| Mar 31, 2025 | 60.09 Mn |
| Dec 31, 2024 | 59.50 Mn |
| Sep 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 58.33 Mn |
| Mar 31, 2024 | 37.94 Mn |
| Dec 31, 2023 | 5.07 Mn |
| Sep 30, 2023 | 38.80 Mn |
| Mar 31, 2023 | 12.91 Mn |
| Jun 30, 2022 | 12.80 Mn |
| Mar 31, 2021 | 98,000.00 |
| Dec 31, 2020 | 391,000.00 |
| Sep 30, 2020 | 781,000.00 |
| Jun 30, 2020 | 781,000.00 |
| Dec 31, 2015 | 11.12 Mn |
| Sep 30, 2015 | 11.56 Mn |
| Jun 30, 2015 | 11.33 Mn |
| Mar 31, 2015 | 11.09 Mn |